These discrepancies between noncompetitive NMDAR antagonists and NMDAR co-agonists on schizophrenia and depressive disorders suggest that direct inhibition of cation channels in NMDAR and enhancement of GluN1 function are not clinically homologous. The gene discussed is GRIN1; the disease is schizophrenia.